20th-banner-rev.png

Albany 2019: 20th Conversation - Abstracts

category image Albany 2019
Conversation 20
June 11-15 2019
Adenine Press (2019)

Antioxidant Enzyme Catalase Activity of Rat Kidney Cells Nuclear Fraction After the Cisplatin and Estradiol Separate and Joint Action

Cisplatin is a widely used and highly effective cancer chemotherapeutic agent. Csplatin-induced cell death involves the activation of multiple pathways of apoptoses as well as oxidant stress activation. These same pathways contribute to the cytotoxic actions of cisplatin on tumor cells. However, it must be noted that cisplatin provided severe undesirable side effects. The most common side effect of cisplatin is nephrotoxicity It is well known that oxidative stress has been recognized as an important factor that contributes to cisplatin nephrotoxicity. Nowadays many efforts have been made to employ drugs and other medicaments as candidate adjuvants to cisplatin to minimize this adverse influence. Steroid hormones such as sex hormones estradiol and progesterone are presently considered as the best adjuvant to cisplatin, are able to prevent intoxication [Grott et al., 2013, Nematbakhsh et al., 2017]. It is well known also, that cisplatin inhibits while estradiol promotes the activity of antioxidant enzymes. The aim of this research was to explore of catalase activity in female rats kidney cells nuclear fraction after the cisplatin and estradiol separate and jointly action. As demonstrated our results cisplatin and estradiol provided opposite effects on catalase activity in case of separate application. In comparison with baseline cisplatin alone action leads to decrease the catalase activity by 24%, whereas after the estradiol separate treatment the activity of this enzyme increases by 26%. The combinated use of cisplatin and estradiol leads to partial recovery of catalase activity. In this case was recorded decrease of enzyme activity by 15%. Achieved results may be helpful for explaining of estradiol attenuating effects in case of its joint use with cisplatin.

References

    M. Grott, S.Karakaya, F. Mayer, F. Baertling, C. Beyer, M. Kipp, H.G. Kopp (2013). Progesterone and estrogen prevent cisplatin-induced apoptosis of lung cancer cells. Anticancer Res. 33(3),791-800.

    M.Nematbakhsh, Z. Pezeshki, F. Eshraghi Jazi et al., (2017). Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences. Asian Pac J Cancer Prev.18(2):295-314.

Zhenya V.Yavroyan
Nune R. Hakobyan
Agapi G. Hovhannisyan
Gevorg A.Avagyan
Emil S. Gevorgyan.

Department of Biophysics
Yerevan State University
Yerevan, Armenia

Ph:(374)77305277
zhen_yav@mail.ru